Detail
| LncRNA Name | FR0257520 |
| Synonyms | NA |
| Region | NA Sequence |
| Ensembl | NA |
| RefSeq | NA |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✘ |
| MiRNA | ✘ |
| Variant | ✔ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | RNA-seq, qPCR etc. |
| Sample | prostate cancer tissues |
| Expression Pattern | down-regulated |
| Function Description | Consistent with the RNA-seq results, PCA3, FR0348383 and MALAT1 overexpression was found in 80% (32/40), 72.5% (29/40), and 82.5% (33/40) of the prostate cancers respectively, whereas decreased FR0257520 expression was found in 82.5% (33/40) of the prostate cancers. |
| Pubmed ID | 22349460 |
| Year | 2012 |
| Title | RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. |
| External Links |
| Links for FR0257520 | GenBank HGNC lncrnadb Noncode |
| Links for prostate cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.